| Business Summary | | Serologicals
Corporation
is
a
worldwide
provider
of
biological
products
to
life
science
companies.
The
Company's
products
are
used
in
the
further
development
of
diagnostic,
vaccine
and
therapeutic
products.
The
Company
provides
value-added,
antibody-based
products
that
are
used
as
the
active
ingredients
in
therapeutic
products
for
the
treatment
and
management
of
diseases
such
as
Rh
incompatibility
in
newborns,
rabies
and
hepatitis
and
in
diagnostic
products
such
as
blood
typing
reagents
and
diagnostic
test
kits.
Through
its
protein
fractionation
facility,
Serologicals
Corporation
provides
a
variety
of
proteins
used
in
the
manufacturing
of
diagnostic
reagents
and
tissue
culture
media
components
for
use
as
additives
in
biotech
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Serologicals
Corp.
is
a
worldwide
provider
of
biological
products
to
life
science
companies.
The
Company's
products
are
used
in
the
further
development
of
diagnostic,
vaccine
and
therapeutic
products.
For
the
six
months
ended
7/1/01,
revenues
fell
31%
to
$53.6
million.
Net
income
totaled
$9.2
million,
up
from
$4.4
million.
Revenues
reflect
the
abences
of
sales
from
Seramed.
Net
income
reflects
a
lower
special
charge
($163
thousand,
down
from
$1.8
million). | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Desmond O'Connell, Jr., 65 Chairman | $207K | -- | David Dodd, 51 Pres,
CEO, Director | 204K | -- | Peter Pizzo III, 34 CFO,
VP-Fin., Sec., Treasurer | 248K | $103K | Toby Simon, M.D., 56 VP,
Medical and Scientific Affairs | 198K | 22K | Sue Sutton-Jones, 48 VP,
Worldwide Regulatory Affairs, Quality Assurance and Compliance | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|